Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Per questa società non c'è ancora un elenco di concorrenti.

• 4/14/2026NEGATIVE
  Telix Pharma Upsizes Convertible Bond Deal to $600 Million

  Telix Pharmaceuticals Ltd. successfully upsized its convertible bond offering to $600 million, exceeding initial expectations and marking Australia's largest such deal this year. Despite the strong demand for the debt issuance, indicating investor confidence in the company's future prospects, Telix's shares experienced a decline. This suggests a potential short-term market reaction to the dilutionary nature of convertible bonds or profit-taking following the announcement.

• 2/26/2026POSITIVE
  1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth

  Telix Pharmaceuticals, a company specializing in radiopharmaceuticals for cancer diagnosis and treatment, is drawing attention as a potential high-growth investment. Analysts suggest its innovative approach to cancer imaging breakthroughs could unlock significant long-term value for investors. The firm's focus on advanced medical solutions positions it favorably within the burgeoning healthcare sector, promising substantial returns for those looking to capitalize on cutting-edge pharmaceutical developments. This outlook highlights Telix as a compelling opportunity for generational wealth creation through medical innovation.